Patents by Inventor Brian Y. Ishida

Brian Y. Ishida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT FOR DARK ADAPTATION
    Publication number: 20100047330
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Application
    Filed: October 6, 2008
    Publication date: February 25, 2010
    Inventors: Daniel M. Schwartz, Keith G. Duncan, Kathy R. Bailey, John P. Kane, Brian Y. Ishida
  • Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
    Patent number: 7470659
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: December 30, 2008
    Assignee: The Regents of the University of California
    Inventors: Daniel M. Schwartz, Keith G. Duncan, Kathy R. Bailey, John P. Kane, Brian Y. Ishida
  • Treatment for dark adaptation
    Patent number: 7470660
    Abstract: The present invention addresses the treatment of age-related macular degeneration, and treatment of individuals with impaired visual function such as impaired dark adaptation, using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration and improving impaired dark adaptation. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: December 30, 2008
    Assignee: The Regents of the University of California
    Inventors: Daniel M. Schwartz, Keith G. Duncan, Kathy Bailey, John P. Kane, Brian Y. Ishida
  • Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and bruch's membrane (BM)
    Publication number: 20040266663
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.
    Type: Application
    Filed: March 5, 2004
    Publication date: December 30, 2004
    Inventors: Daniel M. Schwartz, Keith G. Duncan, Kathy R. Bailey, John P. Kane, Brian Y. Ishida
  • Treatments for age-related macular degeneration (AMD)
    Publication number: 20030229062
    Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.
    Type: Application
    Filed: May 2, 2003
    Publication date: December 11, 2003
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Daniel M. Schwartz, Keith G. Duncan, Kathy R. Bailey, John P. Kane, Brian Y. Ishida